Vivos Therapeutics Q1 FY26 net loss more than doubles to $7.8 million; revenue rises 70% to $5.1 million

• Vivos Therapeutics posted a net loss of $7.75 million, more than doubled from a year earlier, as revenue climbed 70% to $5.14 million.
• Gross margin widened to 60% from 50% a year earlier, while operating expenses jumped 78% to $9.67 million.
• Cash and cash equivalents totaled $2.11 million at March 31, with stockholders’ equity at a deficit of $1.14 million.
• Oral appliance sales volumes rose 42% to 5,304, while revenue from oral appliance sales to legacy VIP dentist customers fell to $1.44 million.
• CEO Kirk Huntsman said the June 2025 acquisition of The Sleep Center of Nevada is driving patient volume and top-line growth, with a “very significant” reduction in customer acquisition costs and efforts underway to improve insurance reimbursement and restructure debt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605201610PRIMZONEFULLFEED9724173) on May 20, 2026, and is solely responsible for the information contained therein.